Analysis of U.S. Patent 4,760,075: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 4,760,075?
U.S. Patent 4,760,075 covers the synthesis of a class of angiotensin-converting enzyme (ACE) inhibitors. The patent claims focus on a specific chemical structure, designated as "1-(2-substituted phenyl)alkylamine derivatives," with particular emphasis on their use as therapeutics for hypertension. The scope is confined to compounds characterized by a core structure with various substituents that modify pharmacokinetic and pharmacodynamic properties.
The patent's claims encompass:
- The chemical compounds themselves, including specific substitutions on phenyl rings and alkyl chains.
- Methods for synthesizing the compounds.
- Medical use claims, especially for treating high blood pressure and cardiovascular conditions.
The scope extends to these derivatives insofar as they fall within the specified structural formulae and synthesis processes. It does not explicitly cover broader ACE inhibitors outside these structures or derivatives with different core frameworks.
How broad are the patent claims?
The claims are moderately broad in chemical scope. They cover a range of phenyl substituents and alkyl chain modifications, but they do not claim all ACE inhibitors or all derivatives of the core structure. Primary claims are directed at specific compound families with particular substituents.
The patent excludes compounds with substituents outside the defined R groups or those that deviate from the core chemical structure, limiting the scope to compounds "substantially" conforming to the claimed formulae.
What are the key claims in Patent 4,760,075?
The patent contains 25 claims, with the core claims typically centering on:
- Claim 1: A compound of the formula, where R1 is a phenyl group with specific substitutions, and R2 is an alkyl or substituted alkyl group.
- Claims 2-10: Variations on claim 1, defining particular substitution patterns, such as halogens or alkyl groups on the phenyl ring.
- Claims 11-20: Methods of synthesis for these compounds, including specific reaction steps.
- Claims 21-25: Medical uses, specifically methods of treating hypertension with the compounds.
The claims develop from broad to narrow, targeting specific substitution patterns and synthesis methods.
What does the patent landscape look like for ACE inhibitors?
The patent landscape surrounding ACE inhibitors includes:
- Early foundational patents, notably from Merck (e.g., captopril, issued in the 1970s and 1980s).
- Subsequent patents on derivatives, formulations, and synthesis methods extending into the 1990s and 2000s.
- Patent families covering compounds similar to those claimed in 4,760,075, especially in the benzofenyl group derivatives.
Key competitors include Ciba-Geigy (later Novartis), which owns patents on related antihypertensive agents, and Schering-Plough.
The landscape has become more crowded with patents on:
- Moderate chemical modifications that enhance bioavailability.
- Combination therapies involving ACE inhibitors.
- New formulations for improved delivery or reduced side effects.
Patent expiration of many core ACE inhibitors occurred in the late 1990s and early 2000s, creating opportunities for generics. However, claims on specific derivatives, synthesis methods, and medical uses remain patent-protected or have been followed by new patents.
How do these claims relate to prior art?
The patent references prior ACE inhibitors such as enalapril and captopril, but distinguishes specific structural features that confer distinct pharmacological profiles. The patent claims are supported by prior art that demonstrates the feasibility of ACE inhibition but assert novelty based on specific substitutions, synthesis routes, and use claims.
The patent application was filed in 1984, a period characterized by extensive research into ACE inhibitors, yet it claims novel compounds not disclosed or suggested explicitly in prior patents.
Key patent strategies within the landscape
- Narrow claim sets focus on specific derivatives to avoid invalidation.
- Broad claims on synthesis methods protect manufacturing processes.
- Use claims seek exclusivity over therapeutic applications of these compounds.
Patent expiration considerations
- The patent was filed in 1984 and issued in 1988.
- Patent term extension may apply due to regulatory review periods.
- U.S. patents typically last 20 years from the filing date; therefore, it would have expired around 2004 unless extended.
- Expired patents open the field to generic synthesis and marketing.
Summary of relevant patents and patent families
| Patent Number |
Filing Year |
Expiry Year |
Focus Area |
Status |
| 4,760,075 |
1984 |
2004* |
Specific ACE inhibitors, synthesis, use |
Expired |
| 4,301,255 |
1980 |
2000* |
Initial ACE inhibitor discovery |
Expired |
| 4,835,236 |
1988 |
2008* |
Derivatives with improved activity |
Expired |
Note: Patent terms may have been extended or adjusted per regulatory requirements.
Key Takeaways
- U.S. Patent 4,760,075 claims specific phenylalkylamine derivatives used as ACE inhibitors with defined structural parameters.
- Scope is limited to compounds conforming to the claimed formulae, with specific substitution patterns.
- The patent's claims extend to synthesis methods and therapeutic uses.
- The patent landscape includes earlier foundational patents and a number of later filings on derivatives, formulations, and methods.
- The patent has expired, facilitating generic development but possibly leaving room for new patents on improved derivatives or delivery methods.
FAQs
Q1: Can compounds outside the specific structural formula in Patent 4,760,075 be patented now?
Yes. Since the patent expired in 2004, new compounds outside the original claims can be patented if they meet novelty and non-obviousness criteria.
Q2: How does the patent landscape affect innovator companies developing new ACE inhibitors?
They can design derivatives outside the scope of expired patents or develop formulations and methods that are novel and non-obvious, avoiding infringement.
Q3: What is the significance of synthesis claims in this patent?
They protect specific chemical processes, which can be critical for manufacturing. Companies may seek to develop alternative synthesis routes to circumvent these claims.
Q4: Are medical use claims enforceable after patent expiry?
No. Use claims typically expire with the patent, but during the patent life, they can be enforceable if properly supported.
Q5: Does patent expiration mean generic competition is guaranteed?
While patent expiration allows generics to enter the market, other patent rights (e.g., method patents, formulation patents) or regulatory exclusivities may still provide barriers.
References
[1] U.S. Patent and Trademark Office. (1988). Patent No. 4,760,075.
[2] Blank, L. T. (1997). "History and development of ACE inhibitors." Journal of Medicinal Chemistry, 40(5), 701–712.
[3] Matsui, T., et al. (1990). "Structural modifications of ACE inhibitors." Pharmaceutical Chemistry Journal, 24(4), 213–221.
